GLP-1 transformation claims on TikTok: what the data says

What did @hopiedopiee1 actually say?

She said one thing clearly: someone is using her image without permission. The creator spent her entire video asking followers to report videos posted by TrimRx, a telehealth company, that apparently feature her likeness. Her words were direct: "I do not go through TrimRx. I do not go through any other telehealth other than Amble." She also said "I do not approve those videos" and described seeing herself pop up on her For You page in content she had nothing to do with. This is not a medical claim. This is a consumer protection and identity complaint.

There is no health advice here, no supplement recommendation, no dosing guidance. What she is describing, a third-party company using her face or footage to imply endorsement, is a real and growing problem in the GLP-1 influencer space. She deserves credit for flagging it publicly rather than quietly.

Does the science back this up?

There is no scientific claim to evaluate here, which is actually worth noting. The creator made zero health claims in this video. But the broader phenomenon she is describing, unauthorized use of influencer content to market telehealth or compounded drug services, is documented and legally significant.

The FTC has published guidance on endorsement fraud and unauthorized use of consumer likenesses in advertising, updated in 2023. The agency explicitly states that using someone's image to imply endorsement without consent is deceptive under Section 5 of the FTC Act. Separately, the FDA has increased scrutiny of how compounded GLP-1 medications, including semaglutide and tirzepatide, are marketed online, particularly after 503B outsourcing facility violations surfaced between 2023 and 2024. Whether TrimRx's specific use of her content violates any of these standards would require legal review, but the concern she raises is not paranoia. It is a real regulatory gray zone that affects patients making decisions about where to seek GLP-1 treatment.

What did they get wrong (or right)?

She got it right. There is nothing medically inaccurate in this video because she did not make medical claims. Her consumer warning is appropriate and her instinct to publicly address it rather than stay silent is the correct move.

One thing she did not say, but probably should have, is that patients should verify any telehealth platform they use through state medical board registries and check whether prescribers are licensed in their state. The fact that a company is using influencer content, with or without permission, tells you almost nothing about whether the underlying medical service is safe or legitimate. TrimRx, like many telehealth platforms operating in this space, would need independent evaluation on clinical grounds. Viewers who see a familiar face and assume that means a platform is trustworthy are making an inference the creator herself is now actively rejecting. That gap between influencer association and platform legitimacy is worth understanding before anyone books a consultation anywhere.

What should you actually know?

If you are choosing a GLP-1 telehealth platform based on which one your favorite creator appears in, stop and reconsider. The creator herself is telling you that her image may appear in content she never agreed to. That is the core problem here.

Here is what actually matters when evaluating a telehealth provider for GLP-1 medications. First, check that the prescribing clinician is licensed in your state. Second, if the platform offers compounded semaglutide or tirzepatide, ask whether the pharmacy is FDA-registered as a 503A or 503B facility. Compounded drugs are not FDA-approved and are not equivalent to brand-name Wegovy, Ozempic, Mounjaro, or Zepbound. Third, look for transparent pricing and a real clinical intake process, not just a quick questionnaire. Fourth, report suspected deceptive advertising to the FTC at reportfraud.ftc.gov. The creator is right that reporting matters. Social platforms acting on mass reports is often faster than regulatory enforcement.

• Unauthorized use of someone's likeness in advertising can violate FTC deceptive advertising rules regardless of how the content was obtained.
• GLP-1 telehealth is a high-growth, loosely regulated market where marketing practices vary widely in quality and honesty.
• Compounded GLP-1 medications are not interchangeable with brand-name versions and carry different risk and quality profiles.
• Platform legitimacy should be evaluated on clinical and regulatory grounds, not influencer association.